Genomic risks for developing CIPN

L. Eckhoff, M. Ewertz

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

Introduction: Chemotherapy-induced Peripheral Neuropathy (CIPN) may occur as a dose-limiting toxicity during chemotherapy with taxanes, and platinum compounds. CIPN may regress after treatment completion, but if it persists it is likely to have a negative impact on quality of life (QoL). So far, the most promising preventive measure is to equip patients with frozen gloves and socks during treatment, but no drugs have been shown to be effective in the prevention of CIPN. Therefore, research efforts have been directed to focus on factors that may predict the occurrence of CIPN prior to treatment. Objectives: Single nucleotide polymorphisms (SNP) are the most common type of genetic variation among people and can be identified by a diverse range of SNP genotyping methods. Methods: A review will be presented of possible associations between SNPs and the risk of CIPN induced by taxanes and platinum compounds. Results: Focus will be on SNPs in drug transporters, detoxification enzymes, genes involved in DNA repair mechanisms, and others. Conclusions: The literature does not give a clear picture of the predictive value of determining SNPs prior to treatment. As the number of long-term cancer survivors increases, a new focus on long-term effects of chemotherapy-induced side effects has emerged. Hopefully in the future, the knowledge gained from application of translational genomics to CIPN will improve the quality of life of cancer survivors.
OriginalsprogEngelsk
ArtikelnummerIS-17
TidsskriftSupportive Care in Cancer
Vol/bind23
Udgave nummerSUPPL. 1
Sider (fra-til)S27-S28
ISSN0941-4355
DOI
StatusUdgivet - 2015
BegivenhedMASCC/ISOO International Symposium - Bella Center, Copenhagen, Danmark
Varighed: 25. jun. 201527. jun. 2015

Seminar

SeminarMASCC/ISOO International Symposium
LokationBella Center
LandDanmark
ByCopenhagen
Periode25/06/201527/06/2015

Emneord

  • *neoplasm *risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity platinum derivative enzyme DNA

Citer dette

Eckhoff, L. ; Ewertz, M. / Genomic risks for developing CIPN. I: Supportive Care in Cancer. 2015 ; Bind 23, Nr. SUPPL. 1. s. S27-S28.
@article{e98c815911c74a169330790a0ceb35c4,
title = "Genomic risks for developing CIPN",
abstract = "Introduction: Chemotherapy-induced Peripheral Neuropathy (CIPN) may occur as a dose-limiting toxicity during chemotherapy with taxanes, and platinum compounds. CIPN may regress after treatment completion, but if it persists it is likely to have a negative impact on quality of life (QoL). So far, the most promising preventive measure is to equip patients with frozen gloves and socks during treatment, but no drugs have been shown to be effective in the prevention of CIPN. Therefore, research efforts have been directed to focus on factors that may predict the occurrence of CIPN prior to treatment. Objectives: Single nucleotide polymorphisms (SNP) are the most common type of genetic variation among people and can be identified by a diverse range of SNP genotyping methods. Methods: A review will be presented of possible associations between SNPs and the risk of CIPN induced by taxanes and platinum compounds. Results: Focus will be on SNPs in drug transporters, detoxification enzymes, genes involved in DNA repair mechanisms, and others. Conclusions: The literature does not give a clear picture of the predictive value of determining SNPs prior to treatment. As the number of long-term cancer survivors increases, a new focus on long-term effects of chemotherapy-induced side effects has emerged. Hopefully in the future, the knowledge gained from application of translational genomics to CIPN will improve the quality of life of cancer survivors.",
keywords = "*neoplasm *risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity platinum derivative enzyme DNA",
author = "L. Eckhoff and M. Ewertz",
year = "2015",
doi = "10.1007/s00520-015-2712-y",
language = "English",
volume = "23",
pages = "S27--S28",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Heinemann",
number = "SUPPL. 1",

}

Genomic risks for developing CIPN. / Eckhoff, L.; Ewertz, M.

I: Supportive Care in Cancer, Bind 23, Nr. SUPPL. 1, IS-17, 2015, s. S27-S28.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - Genomic risks for developing CIPN

AU - Eckhoff, L.

AU - Ewertz, M.

PY - 2015

Y1 - 2015

N2 - Introduction: Chemotherapy-induced Peripheral Neuropathy (CIPN) may occur as a dose-limiting toxicity during chemotherapy with taxanes, and platinum compounds. CIPN may regress after treatment completion, but if it persists it is likely to have a negative impact on quality of life (QoL). So far, the most promising preventive measure is to equip patients with frozen gloves and socks during treatment, but no drugs have been shown to be effective in the prevention of CIPN. Therefore, research efforts have been directed to focus on factors that may predict the occurrence of CIPN prior to treatment. Objectives: Single nucleotide polymorphisms (SNP) are the most common type of genetic variation among people and can be identified by a diverse range of SNP genotyping methods. Methods: A review will be presented of possible associations between SNPs and the risk of CIPN induced by taxanes and platinum compounds. Results: Focus will be on SNPs in drug transporters, detoxification enzymes, genes involved in DNA repair mechanisms, and others. Conclusions: The literature does not give a clear picture of the predictive value of determining SNPs prior to treatment. As the number of long-term cancer survivors increases, a new focus on long-term effects of chemotherapy-induced side effects has emerged. Hopefully in the future, the knowledge gained from application of translational genomics to CIPN will improve the quality of life of cancer survivors.

AB - Introduction: Chemotherapy-induced Peripheral Neuropathy (CIPN) may occur as a dose-limiting toxicity during chemotherapy with taxanes, and platinum compounds. CIPN may regress after treatment completion, but if it persists it is likely to have a negative impact on quality of life (QoL). So far, the most promising preventive measure is to equip patients with frozen gloves and socks during treatment, but no drugs have been shown to be effective in the prevention of CIPN. Therefore, research efforts have been directed to focus on factors that may predict the occurrence of CIPN prior to treatment. Objectives: Single nucleotide polymorphisms (SNP) are the most common type of genetic variation among people and can be identified by a diverse range of SNP genotyping methods. Methods: A review will be presented of possible associations between SNPs and the risk of CIPN induced by taxanes and platinum compounds. Results: Focus will be on SNPs in drug transporters, detoxification enzymes, genes involved in DNA repair mechanisms, and others. Conclusions: The literature does not give a clear picture of the predictive value of determining SNPs prior to treatment. As the number of long-term cancer survivors increases, a new focus on long-term effects of chemotherapy-induced side effects has emerged. Hopefully in the future, the knowledge gained from application of translational genomics to CIPN will improve the quality of life of cancer survivors.

KW - neoplasm risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity plati

U2 - 10.1007/s00520-015-2712-y

DO - 10.1007/s00520-015-2712-y

M3 - Conference abstract in journal

VL - 23

SP - S27-S28

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - SUPPL. 1

M1 - IS-17

ER -